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A  60-year-old  woman  with  past  medical  history  of  chronic
pancreatitis  and  bilioenteric  anastomosis  was  referred  to
our  institution  for  routine  unenhanced  pancreatic  MR  eval-
uation.  Besides  the  expected  ﬁndings  of  uncomplicated
chronic  pancreatitis,  the  study  revealed  several  focal  lesions
distributed  through  the  liver,  suggestive  of  metastases.  They
were  hypointense  in  T1  imaging  and  remarkably  hyperin-
tense  in  T2-weighted  images  (Fig.  1).  Blood  tests  where
mostly  unexceptional,  only  revealing  elevated  gamma-
glutamyl  transferase  [88  U/L  (normal:  5--36  U/L)].
A  liver  biopsy  was  performed  and,  despite  the  obten-
tion  of  only  a  small  amount  of  diagnostic  material,  it  was
still  possible  to  exclude  carcinomatous,  neuroendocrine  and
hepatocytary  origin  and  to  detect  positivity  for  CD34,  a
marker  present  in  tumors  of  hematopoietic  or  endothelial
lineage.1
PET-CT  was  also  realized  for  staging,  demonstrating  mul-
tiple  slightly  hypermetabolic  liver  lesions  and  signiﬁcant
hypermetabolism  centered  in  the  left  aryepiglottic  fold.
After  biopsy  the  neck  lesion  was  diagnosed  as  squamous-cell
carcinoma,  non-related  to  the  liver  lesions.  Neck  MRI  stag-
ing  revealed  invasion  of  the  ipsilateral  piriform  sinus  and∗ Corresponding author.
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esenting  multifocal  epithelioid  hemangioendothelioma.
he  presence  of  an  ipsilateral  level  IV  necrotic  lymph  node
TNM:  T2,N1,M0).
With  these  results  the  possibility  of  a  primary,  multifo-
al,  vascular  liver  malignancy  started  to  gain  strength  and
nother  liver  biopsy  was  taken.  The  samples  were  repre-
entative  and  histological  analysis  revealed  the  presence  of
ests  of  epithelioid  cells  (Fig.  2);  the  immunohistochemical
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Figure  2  Liver  biopsy  specimen  (hematoxylin  &  eosin)  revea-
ling ‘‘nests’’  of  epithelioid  cells.
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Figure  4  Abdominal  MRI,  T2-weighted  image,  axial  plane,
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Tigure  3  Immunohistochemistry  with  anti-cytokeratin
arker  CK  OSKAR® determining  positivity  for  epithelial  cells.
ests  detected  positivity  for  anti-cytokeratin  marker  (CK
SKAR®),  again  suggesting  the  epithelial  nature  of  the  lesion
Fig.  3).  Altogether,  the  ﬁndings  of  both  biopsies  were
ighly  suggestive  of  hepatic  epithelioid  hemangioendothe-
ioma  (EHE).
A  ﬁnal  contrast-enhanced  abdominal  MRI  (Fig.  4) was
aken  just  before  treatment  was  initialized  (4  weeks  after
he  ﬁrst  MRI).  The  liver  parenchyma  was  now  almost  com-
letely  substituted  by  hemangioendothelioma  lesions  that
eveal  progressive  contrast  enhancement  in  the  portal  and
elayed  imaging  phases.
Due  to  massive  hepatic  involvement,  liver  transplanta-
ion  would  be  the  best  therapeutic  option.2 However,  the
ynchronous  laryngeal  tumor  precluded  this  alternative  and
he  patient  started  a  regime  of  IV  bevacizumab,  an  angio-
enesis  inhibitor.  After  2  months  of  clinical  and  tumoral
tability  (MRI  proven),  patient’s  clinical  condition  worsened
nd  a  new  MRI  revealed  progression  of  liver  disease  and
scites.  The  patient  ﬁnally  died  from  respiratory  infectious
omplication.
HEH  is  a  very  uncommon  primary  tumor  of  liver  vascula-
ure,  usually  deﬁned  as  intermediate-grade  malignancy  and
onsidered  one  of  the  less  aggressive  hepatic  malignancies.
A
T
t-weeks  after  initial  MRI.  Progression  of  the  disease  with
ncountable  multifocal  epithelioid  hemangioendothelioma
esions.
evertheless,  there  are  aggressive  cases  with  progressive
umor  growth  leading  to  hepatic  failure,  extra-hepatic
etastases  and  death.3
Three  forms  of  the  tumor  are  recognized:  single  nodular,
ultifocal  and  diffuse  type.  The  majority  of  tumors  corre-
pond  to  the  multifocal-type.  Characteristic  MR  features  of
ultifocal  HEH  include  multiple  hepatic  nodules  usually  cen-
ered  in  the  periphery  of  the  liver,  coalescent,  hypointense
n  T1-weighted  imaging,  heterogeneously  hyperintense  in
2-weighted  imaging  with  progressive,  delayed  contrast-
nhancement.3
When  feasible,  the  most  effective  treatment  is  liver
ransplantation  with  1-year  and  5-year  patient  survival  rates
f  96%  and  54.5%.4 Evidence  suggests  that  even  patients
ith  limited  extra-hepatic  disease  can  be  considered  for
ransplantation.  Other  therapeutic  strategies,  as  the  use  of
ngiogenesis  inhibitors,  can  be  considered  when  transplan-
ation  is  not  an  option.5
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